(NASDAQ: CELC) Celcuity's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Celcuity's revenue in 2025 is $0.On average, 4 Wall Street analysts forecast CELC's revenue for 2026 to be $2,214,674,314, with the lowest CELC revenue forecast at $1,073,395,788, and the highest CELC revenue forecast at $3,695,366,528. On average, 4 Wall Street analysts forecast CELC's revenue for 2027 to be $14,711,334,759, with the lowest CELC revenue forecast at $11,739,470,934, and the highest CELC revenue forecast at $17,694,059,823.
In 2028, CELC is forecast to generate $26,275,540,950 in revenue, with the lowest revenue forecast at $20,693,628,290 and the highest revenue forecast at $34,510,310,995.